| News
Interest from startups in the BaseLaunch healthcare accelerator exceeds expectations
25.07.2017
More than 100 projects from Switzerland and abroad competed for a place in the BaselArea.swiss accelerator program for healthcare startups.
By the closing date of June 30, the BaseLaunch startup accelerator received 112 applications. 77 percent of the projects were from Europe, with a total of 45 percent from Switzerland and 25 projects from the rest of the world. A third of applications involved therapeutics, 20 percent were concerned with diagnostics, and 18 percent with digital healthcare and healthcare services. Other projects focused on therapeutic platforms and services, medtech, and related fields. BaseLaunch offers startups infusions of funds, insight, infrastructure and industry access, and integrates them into one of the most dynamic biotech and healthcare ecosystems in Europe. The accelerator program initiated and operated by BaselArea.swiss aims to attract the next generation of successful healthcare companies by harnessing the unique position of the Basel region as a global life sciences hub. BaseLaunch is backed by healthcare partners Novartis Venture Fund, Johnson & Johnson Innovation and Pfizer. BaseLaunch also collaborates with digitalswitzerland as a healthcare vertical of Kickstart Accelerator.
Positive response to the call for applications
“The number of applicants far exceeded our expectations,” says Alethia de León, Managing Director of BaseLaunch. “We now have the task of selecting up to ten of the most promising projects for the first phase.” A selection committee made up of industry experts will be responsible for the selection process. Ventures accepted for the first phase of the program will receive grants of up to 10,000 Swiss francs beginning in September 2017. They will then have three months to develop their business ideas in close collaboration with the BaseLaunch team and a network of experienced entrepreneurs. Up to three startups will be selected from these companies for the second phase. They will each receive up to 250,000 Swiss francs and the opportunity to generate research data for one year in the laboratory of the Switzerland Innovation Park Basel Area and thereby achieve milestones in their business plan. Experts will also be available to advise and mentor during this time.
For Christof Klöpper, CEO of BaselArea.swiss, the large number of applications from abroad is a sure sign of the Basel region’s international reputation as a world-leading life sciences center. BaselArea.swiss has passed on to BaseLaunch all of its expertise in promoting innovation and investment. “We have many years of experience of networking innovators in the local area and supporting entrepreneurs by identifying suitable partners. BaseLaunch takes full advantage of this expertise, which is particularly valuable to participants from outside the region.”
The selected startups for the first phase will be announced in late summer.
For more information, please visit the BaseLaunch website.
Important dates:
Phase I: September 15 – December 7, 2017
Phase II: January 2 – December 21, 2018
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
BLKB supporting startups in Basel region
Basellandschaftliche Kantonalbank (BLKB) has founded the inQbator startup accelerator. Together with its partners Hemex and Launchpad, the bank will be...
Read MoreBioVersys receives funding in the fight against tuberculosis
The Basel-based pharma company BioVersys has received 2.7 million euros in funding alongside two partners. This financing serves to help...
Read MoreBiosynex takes up residence in Delémont
The French company Biosynex develops analytical, diagnostic and prophylactic medical devices. Its portfolio includes a test for COVID-19. It has...
Read MoreNovartis Campus opening further
Novartis' 25-year anniversary also marks the next step in the ongoing opening of the campus. The Switzerland Innovation Park Basel...
Read Moredocdok.health increases safety of coronavirus vaccinations
The Basel-based start-up docdok.health has developed an app that aims to increase the safety and efficacy of COVID-19 vaccinations. The...
Read MoreHemex attracts Swiss investors
A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The...
Read MoreRhizen drug secures approval in the USA
The United States Food and Drug Administration has granted accelerated approval for the drug Umbralisib. Basel biotech Rhizen has discovered...
Read MoreNovaremed secures US$50 million
Basel biotech Novaremed is receiving US$50 million through an agreement with an investment group. Novaremed will use this financing to...
Read MoreAxtria driving growth from Basel
The US firm Axtria has established a new office in Basel. The company offers services for the life sciences industry...
Read MoreTechnologiepark Basel celebrates its role as a driver of innovation
The Technologiepark Basel will be ten years old in 2021. Over the past decade, it has supported many startups and...
Read More